Spiritual Life Society

In a groundbreaking development, Anavex Life Sciences has reported promising results from a long-term extension study of their investigational therapy, Anavex 2-73, targeting Parkinson’s disease dementia. The study revealed substantial reductions in symptom severity, bringing hope to patients and healthcare providers alike.  Anavex 2-73, also known as blarcamesine, functions by activating SIGMAR1, a receptor protein […]

Anavex Life Sciences has announced promising long-term data for its investigational therapy, Anavex 2-73, in the treatment of Parkinson’s disease dementia. The extension of a Phase 2 trial demonstrated that patients who received Anavex 2-73 experienced a reduction in the severity of their symptoms, contrasting sharply with the symptom progression observed during a drug hiatus.  […]